Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Effect of induction chemotherapy on lung function and exercise capacity in patients affected by malignant pleural mesothelioma.

Marulli G, Rea F, Nicotra S, Favaretto AG, Perissinotto E, Chizzolini M, Vianello A, Braccioni F.

Eur J Cardiothorac Surg. 2010 Jun;37(6):1464-9. doi: 10.1016/j.ejcts.2010.01.008.

PMID:
20153664
2.

Changes in pulmonary function tests predict radiological response to chemotherapy in malignant pleural mesothelioma.

Marulli G, Di Chiara F, Braccioni F, Perissinotto E, Pasello G, Favaretto AG, Breda C, Rea F.

Eur J Cardiothorac Surg. 2013 Jul;44(1):104-10. doi: 10.1093/ejcts/ezs624.

PMID:
23349323
3.

A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.

Yamanaka T, Tanaka F, Hasegawa S, Okada M, Soejima T, Kamikonya N, Fukuoka K, Nakano T.

Jpn J Clin Oncol. 2009 Mar;39(3):186-8. doi: 10.1093/jjco/hyn145.

4.

Monitoring of lung motion in patients with malignant pleural mesothelioma using two-dimensional and three-dimensional dynamic magnetic resonance imaging: comparison with spirometry.

Plathow C, Klopp M, Schoebinger M, Thieke C, Fink C, Puderbach M, Ley S, Weber MA, Sandner A, Claussen CD, Herth F, Tuengerthal S, Meinzer HP, Kauczor HU.

Invest Radiol. 2006 May;41(5):443-8.

PMID:
16625107
5.

Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience.

Lee JD, Perez S, Wang HJ, Figlin RA, Holmes EC.

J Surg Oncol. 1995 Dec;60(4):262-7.

PMID:
8551737
6.

Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations.

Stewart DJ, Martin-Ucar AE, Edwards JG, West K, Waller DA.

Eur J Cardiothorac Surg. 2005 Mar;27(3):373-8.

PMID:
15740941
7.

Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.

Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M.

Jpn J Clin Oncol. 2008 May;38(5):339-46. doi: 10.1093/jjco/hyn024.

8.

Trimodality therapy for malignant pleural mesothelioma.

Buduhan G, Menon S, Aye R, Louie B, Mehta V, Vallières E.

Ann Thorac Surg. 2009 Sep;88(3):870-5; discussion 876. doi: 10.1016/j.athoracsur.2009.05.036.

PMID:
19699914
9.

An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma.

Pasello G, Ceresoli GL, Favaretto A.

Cancer Treat Rev. 2013 Feb;39(1):10-7. doi: 10.1016/j.ctrv.2012.03.001. Review.

PMID:
22459200
10.

Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.

Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh G, Komaki R, McMurtrey MJ, Hong WK.

Cancer. 1995 Dec 1;76(11):2230-6.

11.

[Surgery for malignant pleural mesothelioma].

Giudicelli R.

Rev Pneumol Clin. 2004 Apr;60(2):68-72. Review. French.

PMID:
15133442
12.

The role of muscle flap in preventing bronchus stump insufficiency after pneumonectomy for malignant pleural mesothelioma in high-risk patients.

Beshay M, Carboni G, Hoksch B, Reymond MA, Schmid RA.

Interact Cardiovasc Thorac Surg. 2008 Aug;7(4):621-4; discussion 624-5. doi: 10.1510/icvts.2007.166546.

13.

Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma.

van Ruth S, Baas P, Haas RL, Rutgers EJ, Verwaal VJ, Zoetmulder FA.

Ann Surg Oncol. 2003 Mar;10(2):176-82.

PMID:
12620914
14.

Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.

Friedberg JS.

Semin Thorac Cardiovasc Surg. 2009 Summer;21(2):177-87. doi: 10.1053/j.semtcvs.2009.07.001. Review.

PMID:
19822291
15.

Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.

Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.

In Vivo. 2006 Nov-Dec;20(6A):715-8.

16.

Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma: is it safe?

Utkan G, Yalçin B, Büyükçelik A, Yalçin S.

J Clin Oncol. 2005 Jan 20;23(3):655; author reply 655. No abstract available.

PMID:
15659523
17.

[Hyperthermic chemoperfusion of the pleural cavity in the combined treatment for malignant pleural mesothelioma].

Levchenko EV, Mamontov OIu, Senchik KIu, Barchuk AS, Gel'fond ML.

Vopr Onkol. 2014;60(4):482-5. Russian.

PMID:
25552068
18.

Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis.

Sidi R, Pasello G, Opitz I, Soltermann A, Tutic M, Rehrauer H, Weder W, Stahel RA, Felley-Bosco E.

Eur J Cancer. 2011 Jan;47(2):326-32. doi: 10.1016/j.ejca.2010.09.044.

PMID:
21036600
19.
20.

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force.

Pennucci MC, Ardizzoni A, Pronzato P, Fioretti M, Lanfranco C, Verna A, Giorgi G, Vigani A, Frola C, Rosso R.

Cancer. 1997 May 15;79(10):1897-902.

PMID:
9149015
Items per page

Supplemental Content

Support Center